Patents Issued in March 8, 2018
  • Publication number: 20180064720
    Abstract: Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
    Type: Application
    Filed: November 2, 2017
    Publication date: March 8, 2018
    Inventors: Chin-Ming Chang, Gary J. Beck, Cynthia C. Pratt, Amy L. Batoosingh
  • Publication number: 20180064721
    Abstract: Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
    Type: Application
    Filed: November 2, 2017
    Publication date: March 8, 2018
    Inventors: Chin-Ming Chang, Gary J. Beck, Cynthia C. Pratt, Amy L. Batoosingh
  • Publication number: 20180064722
    Abstract: Pharmaceutical compositions comprising cefepime or a pharmaceutically acceptable salt thereof, tazobactam or a pharmaceutically acceptable salt thereof, and arginine or a pharmaceutically acceptable salt thereof; and their use in treatment, control or prevention of bacterial infection is disclosed.
    Type: Application
    Filed: March 31, 2017
    Publication date: March 8, 2018
    Applicant: WOCKHARDT LIMITED
    Inventors: Manohar Baburao NANDANWAR, Atul KANSAGARA, Rajendra Nandlal NAGORI, Muftedar Ahmed Iftekhar PATEL, Ravindra Dattatraya YEOLE, Bhaskar CHAUHAN, Keshav DEO, Mahesh Vithalbhai PATEL
  • Publication number: 20180064723
    Abstract: A method for treating bacterial infection using: (a) cefepime or a pharmaceutically acceptable salt thereof, (b) arginine or a pharmaceutically acceptable salt thereof, and (c) tazobactam or a pharmaceutically acceptable salt thereof is disclosed.
    Type: Application
    Filed: March 31, 2017
    Publication date: March 8, 2018
    Applicant: WOCKHARDT LIMITED
    Inventors: Mahesh Vithalbhai PATEL, Sachin BHAGWAT, Swapna Shripad TAKALKAR, Rajesh CHAVAN, Kushal UMARKAR
  • Publication number: 20180064724
    Abstract: This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
    Type: Application
    Filed: June 21, 2017
    Publication date: March 8, 2018
    Inventors: Gurudatt A. CHANDORKAR, Jennifer A. HUNTINGTON, Tara PARSONS, Obiamiwe C. UMEH
  • Publication number: 20180064725
    Abstract: The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 8, 2018
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
    Inventors: Hadas REUVENI, Ehud COHEN, Alexander LEVITZKI, Shmuel BEN-SASSON
  • Publication number: 20180064726
    Abstract: Described are deuterium-substituted oxazepin compounds of structural Formula I, which are inhibitors/blockers of the late sodium current. Also described are pharmaceutical compositions comprising the deuterium-substituted oxazepin compounds, and methods of use thereof.
    Type: Application
    Filed: September 7, 2017
    Publication date: March 8, 2018
    Inventors: Richard FISHER, Chengzhi ZHANG
  • Publication number: 20180064727
    Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are selective V1a antagonists for use in the treatment of phase shift sleep disorders, in particular jetlag. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of phase shift sleep disorders comprising a compound according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 8, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick Schnider, Christophe Grundschober
  • Publication number: 20180064728
    Abstract: A method for treating a symptom of a neurodegenerative condition. The method includes topically administering a composition that contains a sex steroid or a cannabinoid or a mixture of both to the forehead, to an area of the outer ear of the subject not including the ear canal, or to both of these anatomical locations. The symptom treatable by the method is a motor symptom or a non-motor symptom.
    Type: Application
    Filed: September 5, 2017
    Publication date: March 8, 2018
    Inventors: Wei-wei Chang, Kenneth I. Sawyer
  • Publication number: 20180064729
    Abstract: The present invention relates to methods of treating, reducing the risk of, preventing, or alleviating a symptom of a pulmonary disease or condition, reducing or suppressing inflammation in the lung, and promoting lung repair, by using a compound of formula A: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 18, 2017
    Publication date: March 8, 2018
    Inventors: Mark Pruzanski, Luciano Adorini
  • Publication number: 20180064730
    Abstract: A small molecule inhibitor for treating a disorder in mammals, wherein the disorder is characterized by high levels of inflammatory components. In a preferred embodiment, the inhibitor comprises cardiac glycosides, also known as cardiac cardenolides. In one example, the drug digitoxin is used to treat the disorder cystic fibrosis. The compounds and methods of the invention are particularly effective for treating cystic fibrosis, a disorder or condition characterized by high levels of inflammation and IL-8.
    Type: Application
    Filed: January 5, 2016
    Publication date: March 8, 2018
    Inventor: Bette Pollard
  • Publication number: 20180064731
    Abstract: The described invention relates to small molecule therapeutic compounds capable of reducing the incidence of intracerebral hemorrhage and brain microhemorrhages identified using zebrafish and mouse models of intracerebral hemorrhage and brain microhemorrhages.
    Type: Application
    Filed: August 2, 2017
    Publication date: March 8, 2018
    Inventors: R. Loch Macdonald, Xiao-Yan Wen, Tom A. Schweizer, Andrew Baker
  • Publication number: 20180064732
    Abstract: The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 8, 2018
    Inventor: Taku KAMBAYASHI
  • Publication number: 20180064733
    Abstract: The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.
    Type: Application
    Filed: October 13, 2017
    Publication date: March 8, 2018
    Inventors: Yoram RICHTER, Gershon GOLOMB, Jonah B. SACHA
  • Publication number: 20180064734
    Abstract: Osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 8, 2018
    Inventor: Herriot Tabuteau
  • Publication number: 20180064735
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Inventor: Herriot Tabuteau
  • Publication number: 20180064736
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 8, 2018
    Inventor: Herriot Tabuteau
  • Publication number: 20180064737
    Abstract: The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 8, 2018
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Publication number: 20180064738
    Abstract: Pharmaceutical compositions are disclosed that comprise at least one compound of formula I: wherein the substituent groups are as defined in the specification, and a pharmaceutically-acceptable excipient. The disclosed pharmaceutical compositions are anti-infective and useful as therapies for the treatment of an infection, including infections associated with a bacteria or a virus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: October 7, 2015
    Publication date: March 8, 2018
    Inventors: Bhupesh Kumar PRUSTY, Dharam V. ABLASHI, Kirk KIMMERLING
  • Publication number: 20180064739
    Abstract: The present disclosure generally relates to pediatric nutritional compositions including a human milk oligosaccharide or a precursor thereof. Further, the nutritional compositions may include a prebiotic mixture of galacto-oligosaccharide and/or polydextrose, a probiotic, such as Lactobacillus rhamnosus GG, and human milk oligosaccharides. The disclosed nutritional compositions advantageously modify gut microbiome and improve select markers of immunity, brain structure, and gut function.
    Type: Application
    Filed: September 6, 2016
    Publication date: March 8, 2018
    Inventors: Maciej Chichlowski, Brian Berg
  • Publication number: 20180064740
    Abstract: The present invention discloses a new use of ginsenoside M1 for treating or preventing gout.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 8, 2018
    Applicant: WELLHEAD BIOLOGICAL TECHNOLOGY CORP.
    Inventors: Sheau-Long LEE, Yu-Chieh LEE, Kuo-Feng HUA
  • Publication number: 20180064741
    Abstract: The present invention discloses a new use of ginsenoside M1 for treating or preventing silicosis.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 8, 2018
    Applicant: WELLHEAD BIOLOGICAL TECHNOLOGY CORP.
    Inventors: Sheau-Long LEE, Yu-Chieh LEE, Kuo-Feng HUA
  • Publication number: 20180064742
    Abstract: In various embodiments, the invention provides a radiotracer comprising a positron emitting atom bound to a deoxy sugar moiety. The radiotracer is reversible bound to a caging moiety that prevents or retards tissue uptake of the radiotracer while the caging moiety is in place. An exemplary caging moiety is acid labile and is cleaved upon uptake of the radiotracer by tissue with an acidic pH.
    Type: Application
    Filed: April 11, 2016
    Publication date: March 8, 2018
    Inventors: David WILSON, Robert FLAVELL
  • Publication number: 20180064743
    Abstract: A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 8, 2018
    Applicant: Technion Research & Development Foundation Limited
    Inventors: Timor BAASOV, Tamar BEN-YOSEF, Igor NUDELMAN, Annie REBIBO-SABBAH, Dalia SHALLOM-SHEZIFI, Mariana HAINRICHSON
  • Publication number: 20180064744
    Abstract: Aspects of the invention include methods of reducing the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a nucleoside agent, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced in a variety of different ways, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.
    Type: Application
    Filed: May 18, 2016
    Publication date: March 8, 2018
    Inventors: Stanley N. Cohen, Ning Deng, Yanan Feng, Tzu-Hao Cheng, Yun-Yun Wu, Wen-Chieh Hsieh
  • Publication number: 20180064745
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 8, 2018
    Applicant: ADURO BIOTECH, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
  • Publication number: 20180064746
    Abstract: The present invention provides an assay that identifies genes required for telomerase-dependent telomere elongation by measuring the de novo telomere addition at a single chromosome.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 8, 2018
    Applicant: The Johns Hopkins University
    Inventors: Carol W. Greider, Stella S. Lee
  • Publication number: 20180064747
    Abstract: This disclosure is directed to structured compositions, including DNA-functionalized scaffolds, for drug capture, and methods and devices for sequestering chemotherapeutics from physiological fluids using the functionalized scaffolds.
    Type: Application
    Filed: September 6, 2017
    Publication date: March 8, 2018
    Inventors: MICHAEL D. SCHULZ, CARL M. BLUMENFELD, ROBERT H. GRUBBS, JULIA R. GREER, DARYL WEI LIANG YEE
  • Publication number: 20180064748
    Abstract: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.
    Type: Application
    Filed: March 27, 2016
    Publication date: March 8, 2018
    Inventors: Eran HORNSTEIN, Irit REICHENSTEIN, Alon CHEN
  • Publication number: 20180064749
    Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.
    Type: Application
    Filed: August 7, 2017
    Publication date: March 8, 2018
    Inventors: Craig L. Duvall, Samantha M. Sarett, Thomas A. Werfel
  • Publication number: 20180064750
    Abstract: In one aspect, the present invention relates to a new method of treating or osteoarthritis in a mammal in need thereof. In certain embodiments, the method comprises contacting at least one biomimetic proteoglycan with the affected joint of the mammal. The biomimetic proteoglycan comprises a core structure and at least one bristle. The biomimetic proteoglycan resists endogenous enzymatic degradation and integrates with the existing tissue matrix.
    Type: Application
    Filed: September 1, 2017
    Publication date: March 8, 2018
    Inventors: Michele Marcolongo, Katsiaryna Prudnikova, Mary Mulcahey, Evan Phillips
  • Publication number: 20180064751
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Application
    Filed: April 14, 2017
    Publication date: March 8, 2018
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • Publication number: 20180064752
    Abstract: The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is —SO3? or —H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.
    Type: Application
    Filed: October 25, 2017
    Publication date: March 8, 2018
    Inventors: MARIA NOWAKOWSKA, KRZYSZTOF SZCZUBIALKA, KRZYSZTOF PYRC, JUSTYNA CIEJKA, MAGDALENA WYTRWAL, ALEKSANDRA MILEWSKA
  • Publication number: 20180064753
    Abstract: The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.
    Type: Application
    Filed: March 17, 2017
    Publication date: March 8, 2018
    Inventors: Julian Norman Kenyon, Paul Rodney Clayton, David Tosh, Fernando Felquer, Ralf Brandt
  • Publication number: 20180064754
    Abstract: A composition including a hydrate form of magnesium oxide, denoted as MgO.(H2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH)2, at a concentration ranging from 0 to 99 wt %; or Mg(OH)2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Applicant: Naveh Pharma (1996) Ltd.
    Inventor: Nitsan PRIMOR
  • Publication number: 20180064755
    Abstract: The present invention relates to a method of treating drug addiction in an individual in need thereof, comprising administering to the individual an effective amount of one or more alkali metals selected from the group consisting of one or more sources of cesium, one or more sources of rubidium, one or more sources of lithium, and combinations thereof. The present invention further relates to compositions comprising one or more alkali metals.
    Type: Application
    Filed: March 4, 2016
    Publication date: March 8, 2018
    Inventor: Arnold Forbes
  • Publication number: 20180064756
    Abstract: To obtain a lifestyle-related disease therapeutic water which comprises a very small amount of anionized silver, nanosized gold, and 99.9% or more of water. A lifestyle-related disease therapeutic water comprising with respect to one liter of water (a), 3-15 mg in silver equivalent of thiosulfate silver ion (b), and 0.1-0.5 mg in gold equivalent of colloidal gold (c).
    Type: Application
    Filed: December 9, 2016
    Publication date: March 8, 2018
    Inventors: Yoshio ICHIKAWA, Taro SHIRAKAWA, Yasushi SEI
  • Publication number: 20180064757
    Abstract: Provided is a non-aqueous formulation for oral teeth, which includes a source of a metal ion and a source of a phosphate ion. The metal ion is chosen from alkaline earth metals, Zn, Zr or any combination thereof, and a molar ratio of the metal ion to the phosphate ion in the formulation is between about 0.01 and about 1.0. The non-aqueous formulation can provide a therapeutic effect.
    Type: Application
    Filed: September 8, 2016
    Publication date: March 8, 2018
    Inventors: Chun-Pin Lin, Hong-Ping Lin, Wei-Yen Yeh
  • Publication number: 20180064758
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an antigen-binding domain with an affinity in the range of 50 nM to 500 nM, wherein said affinity comprises component kinetics such that the association rate constant (kon) is greater than or equal to 1×105 M?1 S?1, and/or the dissociation rate constant (koff) is greater than or equal to 0.01 s?1.
    Type: Application
    Filed: September 5, 2016
    Publication date: March 8, 2018
    Inventors: Martin Pulé, Anne Kramer, Evangelia K. Kokalaki
  • Publication number: 20180064759
    Abstract: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCF4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiating the stem cells, are also provided.
    Type: Application
    Filed: July 13, 2017
    Publication date: March 8, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Keith D. Crawford, Christopher Southgate
  • Publication number: 20180064760
    Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.
    Type: Application
    Filed: August 14, 2017
    Publication date: March 8, 2018
    Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
  • Publication number: 20180064761
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: July 18, 2017
    Publication date: March 8, 2018
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Publication number: 20180064762
    Abstract: Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.
    Type: Application
    Filed: October 30, 2017
    Publication date: March 8, 2018
    Applicants: VA Boston Healthcare System, Schepens Eye Research Institute, Children's Medical Center Corporation
    Inventors: Markus H. Frank, Natasha Y. Frank, Bruce Ksander, Paraskevi Evi Kolovou
  • Publication number: 20180064763
    Abstract: Disclosed herein are methods for cryopreserving, hibernation and room temperature storage of PEC aggregates, implantable semipermeable devices and the VC combination product.
    Type: Application
    Filed: October 26, 2017
    Publication date: March 8, 2018
    Applicant: ViaCyte, Inc.
    Inventors: Alan Agulnick, Laura Martinson, Evert Kroon, Michael Scott, Chad Green
  • Publication number: 20180064764
    Abstract: The invention relates generally to the fields of biology and life sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in morselized amniotic membrane tissue and morselized umbilical cord tissue preparations.
    Type: Application
    Filed: October 6, 2017
    Publication date: March 8, 2018
    Inventors: Scheffer TSENG, Lorraine CHUA
  • Publication number: 20180064765
    Abstract: The present invention is directed to compositions comprising an immune checkpoint inhibitor or a T cell stimulator or a combination thereof, and a live attenuated recombinant Listeria strain comprising a fusion polypeptide comprising a truncated Listeriolysin O protein, a truncated ActA protein, or a PEST amino acid sequence fused to a tumor-associated antigen. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor or a cancer, comprising the step of administering the same.
    Type: Application
    Filed: July 17, 2015
    Publication date: March 8, 2018
    Inventors: Robert PETIT, Anu Wallecha, Samir Khleif, Zhisong Chen, Jay A. Berzofsky
  • Publication number: 20180064766
    Abstract: The present invention relates to a composition for preventing or treating of colitis comprising Lactobacillus sakei K040706 as an active ingredient. More particularly, the present invention relates to a pharmaceutical composition or a food composition for preventing or treating colitis comprising Lactobacillus sakei K040706 (Accession No: KCCM11472P) as an active ingredient. Since Lactobacillus sakei K040706 of the present invention is capable of enhancing immune function such as increasing intestinal NO production ability and reducing the damage of intestinal tissue, Lactobacillus sakei K040706 may be useful for improving and treating colitis.
    Type: Application
    Filed: July 7, 2017
    Publication date: March 8, 2018
    Inventors: Young Kyoung RHEE, Hee-Do HONG, Chang-Won CHO, Mi JANG, Tae-Gyu LIM, Young-Chul LEE, KyungTack KIM, Eun-Young HWANG, Kyung-Tae LEE, Ji-Sun SHIN, Seunghwan SEO, Young-ran SONG
  • Publication number: 20180064767
    Abstract: Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 8, 2018
    Inventor: Elizabeth McKenna
  • Publication number: 20180064768
    Abstract: Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 8, 2018
    Inventor: Elizabeth McKenna
  • Publication number: 20180064769
    Abstract: Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 8, 2018
    Inventor: Elizabeth McKenna